Gyre Therapeutics (GYRE) Change in Accured Expenses (2010 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Change in Accured Expenses of $683000.0 for Q1 2026, down 84.62% year-over-year from $4.4 million in Q1 2025, and down 71.3% quarter-over-quarter from $2.4 million in Q4 2025.
Gyre Therapeutics (GYRE) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Change in Accured Expenses for 17 consecutive years, with $683000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses fell 84.62% year-over-year to $683000.0; the TTM figure through Mar 2026 stood at -$2.8 million (down 157.26% YoY), while the FY2025 annual figure was $946000.0, up 163.19% from the prior year.
- Change in Accured Expenses fell to $683000.0 in Q1 2026 per GYRE's latest filing, from $2.4 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.2 million in Q4 2022 and bottomed at -$4.7 million in Q2 2022.
- Historically, Change in Accured Expenses has averaged $205411.8 across 5 years, with a median of $683000.0 in 2026.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses surged 3441.94% — and 2025, when it tumbled 3275.71%.
- Gyre Therapeutics' Change in Accured Expenses stood at $6.2 million in 2022, then sank by 76.06% to $1.5 million in 2023, then soared by 39.95% to $2.1 million in 2024, then climbed by 13.98% to $2.4 million in 2025, then tumbled by 71.3% to $683000.0 in 2026.
- Business Quant data shows GYRE's Change in Accured Expenses at $683000.0 in Q1 2026, $2.4 million in Q4 2025, and -$3.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 55.78 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 212.44 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 61.62 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 68.82 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn | -502,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -502,000.00 |
| Jun 30, 2026 | -502,000.00 |
| Mar 31, 2026 | 683,000.00 |
| Mar 31, 2026 | 683,000.00 |
| Dec 31, 2025 | 2.38 Mn |
| Dec 31, 2025 | 2.38 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Sep 30, 2025 | -3.51 Mn |
| Jun 30, 2025 | -2.36 Mn |
| Jun 30, 2025 | -2.36 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Mar 31, 2025 | 4.44 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Dec 31, 2024 | 2.09 Mn |
| Sep 30, 2024 | -1.55 Mn |
| Sep 30, 2024 | -1.55 Mn |
| Jun 30, 2024 | -70,000.00 |
| Jun 30, 2024 | -70,000.00 |
| Mar 31, 2024 | -1.97 Mn |
| Mar 31, 2024 | -1.97 Mn |